Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

Anti-BCMA/GPRC5D bispecific CAR T cells achieved a 97% overall response rate in patients with relapsed or refractory multiple myeloma with extraosseous extramedullary disease.

• Why it matters: Patients with this disease subtype have poor outcomes and limited effective treatment options, highlighting the urgent need for new therapies to improve survival and quality of life.
• What they did: A phase 2 trial enrolled 37 patients and administered anti-BCMA/GPRC5D CAR T cells at 2.0 × 10^6 cells/kg, assessing their activity and safety over a median follow-up of 10.1 months.
• The result: The therapy resulted in high response rates, including 43% with stringent complete response, with manageable adverse events, supporting its potential as an effective treatment for this difficult-to-treat population.